India signs cooperation agreement with World Food Programme for 2023-27
Expanding its R&D and manufacturing facility to introduce next gen gummies
New Delhi-based contract development and manufacturing organisation (CDMO) Akums Drugs and Pharmaceutical has announced entry into the nutraceutical gummies segment with a series of novel formulations for wellness and common ailments.
This initiative seeks to cater to a host of conditions, that comes as a solution for adults, paediatrics and geriatric population who are looking for an alternative to conventional dosage forms like tablets, capsules, syrup etc. who no longer find pills/capsules/syrups palatable or convenient.
Sandeep Jain, Jt. Managing Director of Akums said, “The production of our new gummies formulations is done at our state-of-the-art Maxcure Nutravedics plant, a subsidiary of Akums, with proven expertise in nutraceutical, ayurvedic, and health supplements.”
The global gummies market is expected to grow at a CAGR of 7.3% between 2021 and 2028, with current valuations of the segment at around $3.4 to $8 billion. Akums says its venture in gummies manufacturing is a game-changer with all possible combinations of flavours and textures, such as natural, natural identical & artificial colours; pectin, gelatin, and sugar based; low sugar, no added sugar, etc.
Within this year, Akums will be expanding its R&D and manufacturing facility to introduce next gen gummies that will be the first time in the world thus supporting the differentiated requirements of diverse consumers.